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Abstract
Background: Atypical meningiomas are an intermediate grade brain tumour with a recurrence rate of 39–58 %.
It is not known whether early adjuvant radiotherapy reduces the risk of tumour recurrence and whether the
potential side-effects are justified. An alternative management strategy is to perform active monitoring with
magnetic resonance imaging (MRI) and to treat at recurrence. There are no randomised controlled trials
comparing these two approaches.
Methods/Design: A total of 190 patients will be recruited from neurosurgical/neuro-oncology centres across the
United Kingdom, Ireland and mainland Europe. Adult patients undergoing gross total resection of intracranial
atypical meningioma are eligible. Patients with multiple meningioma, optic nerve sheath meningioma, previous
intracranial tumour, previous cranial radiotherapy and neurofibromatosis will be excluded. Informed consent will
be obtained from patients. This is a two-stage trial (both stages will run in parallel):
Stage 1 (qualitative study) is designed to maximise patient and clinician acceptability, thereby optimising
recruitment and retention. Patients wishing to continue will proceed to randomisation.
Stage 2 (randomisation) patients will be randomised to receive either early adjuvant radiotherapy for 6 weeks
(60 Gy in 30 fractions) or active monitoring.
The primary outcome measure is time to MRI evidence of tumour recurrence (progression-free survival (PFS)). Secondary
outcome measures include assessing the toxicity of the radiotherapy, the quality of life, neurocognitive function, time to
second line treatment, time to death (overall survival (OS)) and incremental cost per quality-adjusted life year (QALY)
gained.
Discussion: ROAM/EORTC-1308 is the first multi-centre randomised controlled trial designed to determine whether
early adjuvant radiotherapy reduces the risk of tumour recurrence following complete surgical resection of atypical
meningioma. The results of this study will be used to inform current neurosurgery and neuro-oncology practice
worldwide.
Trial registration: ISRCTN71502099 on 19 May 2014.
Keywords: Atypical meningioma, Radiotherapy, Survival, Outcome
* Correspondence: michael.jenkinson@liv.ac.uk
1Department of Neurosurgery, The Walton Centre NHS Foundation Trust,
Liverpool L9 7LJ, UK
7Institute of Translational Medicine, University of Liverpool, Liverpool L69 7BE,
UK
Full list of author information is available at the end of the article
TRIALS
© 2015 Jenkinson et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jenkinson et al. Trials  (2015) 16:519 
DOI 10.1186/s13063-015-1040-3
Background
Meningiomas arise from the linings of the brain, account
for 25 to 33 % of adult primary brain tumours and have
a peak incidence at age 40 to 60 years [1]. The World
Health Organisation (WHO) [1] classifies three grades:
1. Benign (grade I) meningioma (approximately 90 %)
2. Atypical (grade II) meningioma (approximately 7 %)
3. Anaplastic (grade III) meningioma (approximately 3 %)
The annual UK incidence of atypical meningioma is
estimated at 0.2 to 0.5/100,000 per year and approxi-
mately 150 undergo surgical resection each year. Since
the publication of the 2000 WHO classification, the re-
ported incidence of atypical meningioma has risen to 20
to 35 % [2–4]; nevertheless, they remain uncommon.
The primary treatment for symptomatic or enlarging
atypical meningioma is surgical excision, and the com-
pleteness of the resection is an important prognostic fac-
tor [5]. Simpson defined the extent of resection into five
categories [5]:
 Simpson 1: complete tumour removal, including
dural attachment and any abnormal bone
 Simpson 2: complete tumour removal, with
coagulation of dural attachment
 Simpson 3: complete tumour removal, without
resection or coagulation of its dural attachment
 Simpson 4: partial tumour removal
 Simpson 5: biopsy only
In modern neurosurgery Simpson 1–3 constitute gross
total resection (GTR), and Simpson 4–5 constitutes sub-
total resection (STR).
Benign (grade I) meningiomas have a low risk of re-
currence (approximately 10 % at 5 years) following sur-
gical resection and are managed by active monitoring
with magnetic resonance imaging (MRI) scans. For ana-
plastic (grade III) meningioma, adjuvant radiotherapy is
indicated following surgery to prolong time to recur-
rence; however, the 5-year progression-free survival is
only approximately 10 % [6]. In atypical meningioma
(grade II), the 5-year tumour recurrence rates are re-
ported as between 39 and 58 %, and in those patients
with residual solid tumour, radiotherapy is administered
to reduce the risk of recurrence. However, in patients
with gross total resection the role of early adjuvant
radiotherapy has not been defined, and the options of
radiotherapy or active monitoring are discussed with
individual patients. Whilst radiotherapy has been shown
to be an effective adjuvant treatment in some studies [7,
8] but not others [2, 9, 10], no consensus exists as to
which of these approaches is best. A recently published
systematic review concluded that since atypical meningi-
oma preferentially recur within 5 years, future studies
should investigate the role of early adjuvant radiotherapy
in these patients [11]. There have been no randomised
controlled trials in this tumour population. Currently,
the treatment decision for adjuvant radiotherapy varies
according to the patient, surgeon and neuro-oncologist
preference [12, 13], and some European expert opinion
Fig. 1 ROAM/EORTC 1308 study design
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recommends that all atypical meningioma patients
should have radiotherapy (http://meningiomauk.org/
radiotherapy/). No agreement exists on the current
standard of care for patients with atypical meningi-
oma undergoing complete resection. Whilst the use
of radiotherapy may obviate the need for further sur-
gical procedures, this must be balanced against the
potential risks of radiotherapy (from 3.4 to 16.7 %
[11]), which include neurocognitive impairment, hypo-
pituitarism and radiation-induced tumours. Equally,
tumour recurrence can also affect neurocognitive
function (NCF) and quality of life (QoL). Tumours
that recur can be treated with further surgery and
radiotherapy.
ROAM/EORTC-1308 (Radiotherapy versus Observation
following surgical resection of Atypical Meningioma) was
funded to determine whether early adjuvant radiotherapy
reduces tumour recurrence compared to active monitor-
ing in patients with newly diagnosed atypical meningioma
who have undergone gross total resection.
Primary objective
The primary objective of the study was to determine
whether early adjuvant fractionated radiotherapy reduces
the risk of tumour recurrence compared to active moni-
toring in newly diagnosed atypical meningioma.
Secondary objectives
The secondary objectives were as follows:
1. To assess the early and late effects of fractionated
radiotherapy
2. To assess and compare quality of life in patients
with atypical meningioma according to the
treatment arm
3. To assess and compare the neurocognitive function
in patients with atypical meningioma according to
treatment arm
4. To record the second-line treatments (surgery,
radiotherapy, and radiosurgery) used at tumour
recurrence according to the treatment arm
5. To determine the overall survival (OS) at 5 years
6. To assess the cost-effectiveness of adjuvant radiother-
apy compared to active monitoring (UK sites only)
7. To correlate proliferation rate and molecular
characteristics with time to tumour recurrence
(separate research funding will be sought).
Methods/Design
Design overview
ROAM/EORTC-1308 is an international, multi-centre,
phase III, randomized controlled trial comparing early
adjuvant radiotherapy (intervention) with observation
(comparator) in patients who have undergone gross total
resection of an intracranial atypical meningioma. This is
a two-stage trial, and both stages will run in parallel:
Stage 1 (qualitative study)
The stage is designed to maximize patient and clinician
acceptability, thereby optimizing recruitment and reten-
tion. Patient permission will be sought to allow audio-
recording of the consultations during which patients are
approached for recruitment to the trial. The qualitative
study will examine how information about the trial is
exchanged by clinicians and patients as they discuss
ROAM and consent is sought. As well as audio-recording
the recruitment consultations, a qualitative researcher will
subsequently interview a sub-sample of patients and clini-
cians. The qualitative study will draw on previously de-
scribed methods [14–16] to identify the source of any
recruitment difficulties and design bespoke strategies to
optimise recruitment. This approach has demonstrated
success in enhancing recruitment in previous trials [17]
and aims to improve the patient experience by improving
information exchange and communication. Specifically,
the qualitative study will compare discussions during re-
cruitment consultations, with clinicians’ and patients’ in-
terpretations of these consultations.
Stage 2 (randomization)
In stage 2, patients will be randomized in a 1:1 ratio to
early adjuvant radiotherapy (60 Gy in 30 fractions) for
6 weeks (intervention) or active monitoring with MRI
(comparator).
Research setting
The trial will be conducted across 20 adult regional
neurosurgery units in the UK and Ireland. As part of an
intergroup collaboration with the European Organisation
for Research and Treatment of Cancer (EORTC) the trial
will also open in 22 centres in mainland Europe. A feasi-
bility survey completed by 10 UK centres provided infor-
mation on the number of eligible patients and confirmed
that the sample size is achievable.
Neurocognitive function assessment
NCF will be assessed using a standard validated battery
of tests to measure verbal and visual memory, executive
skills, processing speed, language, working memory,
mood and visuo-spatial construction. These are import-
ant parameters to assess and determine whether radio-
therapy has any adverse impact on neurocognitive
function in patients with meningioma. The following
tests will be used: Hopkins Verbal Learning Test, REY
Complex Figure Test, Dass21, Stroop Trail Making Test,
Symbol Digit Modality Test, WAIS-IV (Digit Span and
Blocks Test), Graded Naming Test and Benton Verbal
Fluency Test. Additionally, consent will be sought for
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longer term follow up NCF assessment 5 years after sur-
gery to assess the later effects of treatment in both the
radiotherapy and observation arms.
Patient and public involvement
The involvement of consumers has been fundamental to
the design of this trial, and it is recognised that patients
and carers have unique experience and expertise, which
they can bring to this study. This enables them to be
part of the solution to the problems faced by researchers
when designing a trial. They have played an active role
in the idea generation, trial design and funding applica-
tion. Their voice will continue to play a significant role
in the preparation and execution of this study and the
dissemination of results.
Funding and ethics approval
The ROAM trial is funded by a £1.36 million grant from
the National Institute of Health Research Health Technol-
ogy Assessment (NIHR-HTA) programme (project num-
ber 12/173/14). MDJ is the chief investigator and MJ is
the co-chief investigator. The study protocol, patient
information sheets and consent forms received ethical
approval from the North East Newcastle and North
Tyneside 2 Research Ethics Committee (ref: 15/NE/0013).
Additionally, this trial will be funded by a €230,000 grant
from the Brain Tumour and Radiation Oncology groups
of the EORTC, which will facilitate the trial opening in
mainland Europe. DCW is the lead for the intergroup col-
laboration with the EORTC.
Study population
The trial will be open to all adult patients with atypical
meningioma who meet the eligibility criteria.
Inclusion criteria
For inclusion, each patient must meet the following criteria:
1. Histologically confirmed newly diagnosed solitary
atypical meningioma (WHO grade II) based on the
2007 WHO criteria [1]
2. Age ≥ 16 years
3. All anatomical locations allowed except optic nerve
sheath tumour
4. Complete resection (Simpson 1, 2 or 3) as assessed
by the surgeon
5. Able to commence radiotherapy between within
12 weeks of surgery (ideally 8 to 12 weeks)
6. WHO performance status 0, 1 or 2
7. Women of reproductive potential must use
effective contraception for the whole duration
of the treatment
8. Absence of any psychological, familial, sociological
or geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule; those conditions should be discussed with
the patient before registration in the trial.
Exclusion criteria
Patients exhibiting any of the following will be excluded
from the study:
1. Neurofibromatosis type II (NF-2)
2. Optic nerve sheath tumours
3. Multiple meningiomas
4. Radiation induced meningioma
5. Clinical evidence of second malignancies, except a
history of cervix carcinoma in situ and/or basal cell
carcinoma
6. Previous intracranial tumour
7. Pregnant or lactating women.
Primary endpoint
The primary endpoint will be the time to MRI evidence
of tumour recurrence or death due to any cause (dis-
ease-free survival (DFS))
Secondary endpoints
The secondary endpoints will include the following:
1. Toxicity assessed by CTCAE (Common
Terminology Criteria for Adverse Events)
2. Quality of life
3. Neurocognitive function
4. Time to second-line (salvage) treatment (surgery,
radiotherapy, and radiosurgery)
5. Time to death (overall survival (OS))
6. Health economic analysis (incremental cost per
QALY gained)
Disease-free survival (DFS) will be counted from the
date of surgery until the date of MRI evidence of tumour
recurrence or death due to any cause. Only clear dural
thickening at the distinction of the investigator is to be
considered tumour.
Overall survival (OS) will be counted from the date
of surgery until death due to any cause.
Randomisation
Patients will be randomised to early radiotherapy or ob-
servation in a ratio of 1:1. Written informed consent will
be obtained following surgical resection and histopatho-
logical confirmation of an atypical meningioma.
Proposed sample size
Atypical meningioma 5-year tumour recurrence rates
are reported as between 39 and 58 %. A 0.05 level two-
sided log-rank test for equality of survival curves with
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80 % power would require 86 patients in each arm (total
number of events required = 46) to detect an absolute
reduction from 40 % in the control group arm to 20 %.
A strong magnitude of effect is required to impact clin-
ical practice and establish a treatment policy across the
NHS in the UK. This is due in part to the expense of
radiotherapy but also the burden to patients - due to the
side effects of radiotherapy (hair loss, skin irritation,
cognitive decline, and secondary malignancy) and its de-
livery requiring patients to attend the hospital daily
(Monday through Friday) for 6 weeks. Patient retention
will be high as patients with atypical meningioma are
routinely followed up for the long term, and data will be
collected at routine clinic visits. However, an adjustment
to allow for a 10 % loss to follow-up has been made,
requiring a total of 190 patients to be recruited. This
sample size calculation has been agreed upon with the
EORTC. The UK arm of the trial will aim to deliver 118
participants with a total of 29 events providing 60 % power.
The remaining participants would be recruited across
Europe within the EORTC intergroup collaboration.
Statistical analysis
The trial will be analysed and reported using the
‘Consolidated Standard of Reporting Trials’ (CONSORT)
and the International Conference on Harmonisation E9
guidelines. A full and detailed statistical analysis plan
will be developed prior to the final analysis of the trial.
The main features of the statistical analysis plan are in-
cluded here.
The primary analysis will be by intention-to-treat
principle, as far as is practically possible. Results will be
presented throughout using 95 % confidence intervals
and a 5 % level of statistical significance. Time to event
outcomes will be analysed using Kaplan Meier curves,
log rank tests and Cox Proportional Hazards models.
Assumptions of proportional hazards will be investi-
gated. Ordinal categorical outcomes will be analysed
using an ordinal logistic model. Continuous outcomes
will be assessed using ANCOVA methods.
Heath economic analysis
There are no existing economic studies of treatment op-
tions in atypical meningioma, and to assess the balance
of the potential benefits of reduced recurrence rates
against the costs, we will conduct a cost-utility ana-
lysis from the perspective of the NHS. Resource use
will be based on entries made in designated sections
of patients' case report forms, Hospital Episode Statis-
tics data sourced from the Health and Social Care
Information Centre for patients recruited in England,
and data from the hospital Patient Administration Sys-
tems as indicated below:
1. The CRF will be used to record data on procedures
and interventions as well as dates of patient transfers
both within and between hospitals from admission
to discharge.
2. Six months after randomising the last patient at
each recruiting centre, the Finance departments
of each centre will be contacted, and a request
submitted for Ward name, ward speciality, the
average cost per bed day on the ward, and the
financial year to which the costs refer. The
Information Technology or Patient Administration
Departments of each centre will also be contacted,
and a request will be submitted (via the CTRC,
to maintain patient anonymity) for the Patient
NHS Numbers (or some other means of linking
the patient to the trial), ward name, ward
speciality (if possible), start date on the ward,
end date on the ward, and number of occupied
bed days on the ward.
3. Data on Hospital Episode Statistics (HES) from the
beginning of the financial year prior to baseline, to
5 years follow-up will be accessed centrally via
biennial downloads from the Health and Social Care
Information Centre.
Unit costs will be obtained from NHS reference costs.
The number of QALY gained will be estimated by ad-
ministering the EQ-5D-5 L and applying a UK tariff for
generating utilities. An economic (Markov) model will
be specified with appropriate health states to project
lifetime costs and consequences. Costs and QALYs oc-
curring after the first year will be discounted at 3.5 %
per annum. Incremental cost-effectiveness ratios will be
compared with threshold values, and the joint uncer-
tainty in costs and benefits considered (in the trial-based
analysis) through the application of bootstrapping and
(in the model) using probabilistic sensitivity analysis to
generate cost-effectiveness acceptability curves.
Translational research studies
The authors have an established brain tumour biobank
(Walton Research Tissue Bank- WRTB; North Wales
REC No 11/WNo03/2). Consent will be sought from pa-
tients for tumour tissue and serum banking, use of sam-
ples for future research projects including genetics
studies, and for collaboration with academic and com-
mercial partners. Tumour tissue (paraffin-embedded and
snap-frozen, if available) from surgery will be sent to the
WRTB. Serum samples will be taken when the patient
undergoes each MRI scan and sent to the WRTB. Future
translational research themes will include the following:
1. MRI - Volumetric measurements will be used to
determine tumour recurrence. The effects of
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radiotherapy on normal brain adjacent to the
resection cavity will be studied.
2. Tumour biology - to investigate whether genetic,
epigenetic or biochemical factors explain individual
variation in tumour recurrence and response to
radiotherapy.
3. Serum analysis - to investigate biomarkers of
tumour recurrence.
Dissemination of results
The communication and dissemination strategy will ac-
tively involve participating centres, their staff and service
users and the professional bodies involved (for example,
Society of British Neurological Surgeons and the EORTC)
and relevant charitable organisations (including brain-
strust, The Brain Tumour Charity, and Brain Tumour
Research). Communication and dissemination of results
will be assisted by members of the study team, including
using social networking sites. Findings of the trial will also
be presented at National and International meetings of
relevant professional bodies and research groups. The
results of the trial will be published in peer-reviewed
journals.
Discussion
This protocol describes the design of a randomised con-
trolled trial to evaluate the clinical effectiveness and
cost-effectiveness of early adjuvant radiotherapy for re-
ducing tumour recurrence in patients undergoing gross
total resection of atypical meningioma. This is the first
randomised controlled to compare early adjuvant radio-
therapy with active monitoring. This study will inform
clinical practice and generate a high quality tumour and
serum biobank in a cohort of atypical meningioma
patients.
Trial status
The trial is scheduled to open in 2015 (http://
www.nets.nihr.ac.uk/projects/hta/1217314).
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